Vor Bio price target lowered to $16 from $17 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on Vor Bio to $16 from $17 and keeps a Buy rating on the shares following its Q4 earnings and corporate update. The recent disclosure of "encouraging" proof-of-concept data from the P1 VBP101 trial serves as a "significant de-risking event" for the asset and platform, the analyst tells investors. Further, the firm expects a number of incremental updates from this trial throughout FY23 to serve as a tailwind for the stock.